SkinBioTherapeutics – updates on acne consumer study and trading, Strong Buy on a winning share tip, target 50p+
By HotStockRockets | Friday 27 October 2023
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
SkinBioTherapeutics (SBTX) has announced that it is commencing a consumer study which it considers “is potentially a major step towards the commercialisation of a new probiotic treatment that could address the root causes of conditions like acne”, as well as noting “trading for the full year to June 2023 was in line with market expectations. Cash at year end was £1.3m, ahead of expectations of £1.1m, and the company continues to control its costs”. What of this news from a current 27p share price, £46.7 million market cap?
You must be a registered member to read this story
ShareProphets is reader-supported journalism
Join us for free and gain access to three articles per month
Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.